Recognition of 'pathogen-associated-molecular-patterns' by Toll-like receptors (TLRs) is considered to be important for an appropriate immune response against pathogens that enter the lower airways. We studied the effects of two different TLR-agonists relevant for respiratory infections in the human lung: lipoteichoic acid (LTA, TLR2-agonist, component of gram-positive bacteria) and lipopolysaccharide (LPS, TLR4-agonist, component of gram-negative bacteria). Therefore, fifteen healthy subjects were given LPS or LTA: by bronchoscope sterile saline was instilled into a lungsegment followed by instillation of LTA or LPS into the contralateral lung. After 6 hours a bronchoalveolar lavage was performed and inflammatory parameters were determined. Isolated RNA from purified alveolar macrophages was analyzed by multiplex-ligationdependent-probe-amplification. Additionally, spontaneous cytokine release by alveolar macrophages was measured. Marked differences were detected between LTA-and LPS-induced lung inflammation. Whereas both elicited neutrophil recruitment, only LPS instillation was associated with activation of neutrophils (CD11b surface-expression, degranulation product levels) and consistent rises of chemo-/cytokine levels. Moreover, LPS but not LTA activated alveolar macrophages, as reflected by enhanced expression of ten different mRNAs encoding pro-inflammatory mediators and increased spontaneous cytokine release upon incubation 'ex vivo'. Remarkably, only LTA induced C5a release. This is the first study to report the in vivo effects of LTA in men and to compare inflammation induced by LTA and LPS in the human lung. Our data suggest that stimulation of TLR2 or TLR4 results in differential pulmonary inflammation, which may be of relevance for understanding pathogenic mechanisms at play during gram-positive and gram-negative respiratory tract infection.
Introduction
Bacterial pneumonia, often caused by gram-positive pathogens, is the most frequent source of sepsis and has a mortality rate of 22% for patients admitted to the Intensive Care Unit 1 . Because of the high incidence of pneumonia and the accompanying high morbidity and mortality, it is important to gain more insight into the pathogenesis of this prominent infectious disease. Phagocytic cells involved in host defense recognize pathogens through highly conserved motifs (pathogen-associated molecular patterns; PAMPs) leading to activation of intracellular signaling cascades and ultimately resulting in a pro-inflammatory response and activation of the innate immune system 2, 3 . Examples of PAMPs include lipopolysaccharide (LPS), part of the outer membrane of gram-negative bacteria, and lipoteichoic acid (LTA), a major constituent of gram-positive bacteria 4 . PAMPs are recognized by 'pattern-recognition receptors' (PRRs) displayed by host cells involved in the innate immune response 2 .
Toll-like receptors (TLRs) are important for an appropriate immune response against pathogens that enter the lower airways 5, 6 . While much has been learned about the pulmonary host response to gram-negative infections and the importance of LPS therein, less is known about the innate immune response against gram-positive pathogens. LPS induces lung inflammation via TLR4 7, 8 and inhalation or bronchial instillation of LPS induced mild inflammation in the bronchoalveolar space of healthy humans [9] [10] [11] . LTA shares many biological properties with LPS and is able to induce the production of a variety of pro-inflammatory cytokines and chemokines by cells of the innate immune system [12] [13] [14] [15] . From in vitro studies it is known that the cellular recognition and signaling receptor for LTA is TLR2 [16] [17] [18] [19] [20] [21] . In addition, in vivo experiments conducted in our laboratory have indicated that LTA induces neutrophil influx and cytokine release via TLR2, i.e. TLR2 gene deficient mice did not mount an inflammatory response in the lung to LTA administered via the airways (Knapp S, unpublished data).
Although many investigations have been published on the effects of LPS in humans 22, 23 , the human response to LTA in vivo has never been studied. Knowledge of the effects of LTA in humans is important considering the prominent place of grampositive pathogens in both community-acquired and nosocomial infections. In the present study we sought to compare the inflammatory responses elicited by LTA and LPS in the human lung, using the well-established model of segmental instillation. Moreover, to determine the possible differential responsiveness of alveolar macrophages, which are considered major effector cells in pulmonary host defense 5, 24 , we also investigated the effects of LTA and LPS on inflammatory gene expression profiles in isolated alveolar macrophages. This study has been described in an abstract 25 . 22 ⏐ Chapter 2
Materials and Methods

Subjects
Twenty-three non-smoking males (age 22.0±0.5 yrs) were recruited by advertising. Screening, consisting of a questionnaire, physical examination, routine blood and urine investigation, electrocardiogram and spirometry, did not reveal any abnormality. The study was approved by the institutional ethics and research committees; written informed consent was obtained from all subjects before enrollment in the study.
Materials
LTA, from Staphylococcus aureus (DSM 20233), was produced as described 26, 27 . The LTA preparation was >99% pure, no contamination with lipopeptides was detected using photometric measurements (UV absorption) and NMR examination. LTA contained <50 pg endotoxin/mg LTA as determined by the Limulus amoebocyte lysate assay 26, 27 . This preparation has been tested extensively for its potency to induce cell activation and inflammation in vitro and in animals in vivo 12, 17, 28 .
LPS was derived from
Escherichia coli (United States Pharmacopeial Convention, Lot G, Bureau of Biologics, United States Food and Drug Administration, Rockville, MD). The in vivo response of humans to this LPS preparation is dependent on TLR4 29 .
Study design
Sterile saline (10 ml) was instilled into a lung subsegment (the right middle lobe or lingula) followed by instillation of either LTA or LPS (in 10 ml saline) into the contralateral lung, using a flexible video bronchoscope. First a dose-escalating study was done with LTA, since this compound had never been administered to humans before. Four subjects received LTA 4 ng/kg bodyweight, followed by four subjects receiving 20 ng/kg. After this initial study and based on the degree of inflammatory responses, seven subjects received LTA 100 ng/kg. Eight subjects received LPS 4 ng/kg, which was identical to that used in previous studies 9, 10 . Vital variables were measured on an hourly basis; volunteers had no complaints and were completely ambulant.
Bronchoalveolar lavage
A bilateral bronchoalveolar lavage (BAL) was performed 6 hours post-challenge in a standardized fashion according to the guidelines of the American Thoracic Society, using a flexible video bronchoscope. Seven successive 20 ml aliquots of pre-warmed 0.9% saline were instilled in the saline-challenged subsegment of the lung and each aspirated immediately with low suction. This procedure was repeated in the LPS-or LTA-challenged subsegment of the contralateral lung. Cell differentials were 
Assays
Myeloperoxidase (MPO) 30 , bactericidal/permeability-increasing protein (BPI), elastase, epithelial cell-derived neutrophil attractant 78 (ENA-78) 11 , growth-related gene-alpha (GRO-α), soluble TNF receptor type I (R&Dsystems, Minneapolis, MN) and C5a (BD Biosciences, San Diego, CA) were determined by ELISA. IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α were measured using a cytometric bead array 11 . Interferon-γ-inducible protein (IP)-10 and monocyte chemoattractant protein (MCP)-1 were detected in BALF using multiplex bead flow assays (Luminex, Bio-rad Laboratories, Inc., Hercules, CA).
Flow cytometric analysis of neutrophils
Expression of CD11b on neutrophils in BALF was determined by flow cytometric analysis using fluorochrome-conjugated mouse anti-human CD15, HLA-DR and CD14 (BD Pharmingen, San Diego, CA) and CD11b antibody (eBioscience, San Diego, CA) in combination with isotype controls. Neutrophils were selected using side scatter (SSC), CD14 and CD15 (CD14-/CD15+ cells were defined as neutrophils). Using this gate definition, neutrophils can be discriminated from alveolar macrophages (CD14+/CD15-) and lymphocytes (SSC low/HLA-DR+).
Isolation of alveolar macrophages BAL fluid (BALF) was immediately centrifuged for 10 min at 1200 rpm at 4°C. BALF cells were passed over a 40 µm nylon filter (BD Falcon, Bedford, MA) and resuspended in ice-cold sterile automated magnetic cell sorting and separation (autoMACS) buffer (PBS, 0.5% bovine serum albumin, 2 mM EDTA; pH=7.4). Subsequently, cells were incubated for 15 min with CD71 microbeads (Multenyi Biotec, Bergisch Gladbach, Germany) at 4°C. Cells were washed again in autoMACS buffer and purified by autoMACS (Multenyi Biotec). Total and viable cell counts were determined before and after the isolation procedure using a Burker-Turk haemocytometer and trypan blue (Emergo, Landsmeer, the Netherlands). Additionally, cytospins were prepared before and after autoMACS and stained with Giemsa. Total and differential cell counts revealed a recovery of 35-40% macrophages and a purity of isolated macrophages of >95% in all groups. After isolation, alveolar macrophages were dissolved in RNAeasy lysis Buffer (buffer RLT, QIAGEN, Hilden, Germany) and stored at -80°C until used for RNA isolation. 24 ⏐ Chapter 2
Multiplex ligation-dependent probe amplification RNA was isolated (RNeasy Mini kit, QIAGEN, Hilden, Germany) and analyzed by multiplex ligation-dependent probe amplification (MLPA) as described previously 31, 32 using an inflammation-specific kit developed in collaboration with MRC-Holland (Amsterdam, the Netherlands) for the simultaneous detection of 40 target genes. Levels of mRNA for each gene were expressed as a normalized ratio of the peak area divided by the peak area of the β2 microglobulin mRNA, to give the relative abundance of mRNAs of the genes of interest 31, 32 .
Spontaneous cytokine release by alveolar macrophages 
Statistical analysis
Values are expressed as mean±SEM. Data were checked for normal distribution and equal variances using the residuals. Depending on the results of these tests, data were analyzed either parametrically or nonparametrically. Statistical comparisons were made by paired t-test or Wilcoxon signed rank test to establish significance between separate datasets. Dose-dependant increases were analyzed by Kruskal-Wallis test (Figure 2 .6). These analyses were performed using SPSS (version 12.0.1; SPSS Inc., Chicago, IL). A P-value of less than 0.05 was considered to represent a statistically significant difference.
Results
Clinical signs
Instillation of saline in one lung segment and LTA or LPS in the contralateral lung was well tolerated and was not associated with clear symptoms. A modest rise in body temperature was recorded 6 hours after bronchial instillation, which reached Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans ⏐ 25 significance in volunteers who received LPS (0.7 ± 0.2 °C; p<0.05), not in volunteers who received LTA (0.6 ± 0.4 °C). Both LTA and LPS caused a significant rise in neutrophil counts in blood (LTA from 2,6 ± 0,2 to 4,1 ± 0,8 x 10 9 /l; LPS from 2,9 ± 0,2 to 4,7 ± 0,5 x10 9 /l; both P<0.05). Bronchial instillation of LPS was associated with a modest increase in plasma IL-6 concentrations to 4,5 ± 1,4 pg/ml (P<0.05), whereas plasma IL-6 did not change after administration of LTA (data not shown).
Leukocyte recruitment
Instillation of LTA resulted in a profound dose-dependent increase in the total number of cells recruited into BALF 6 hours post-challenge compared to instillation of saline in the contralateral lung (Figure 2 .1A). The increase in total cell number was due to a dose-dependent rise in the number of neutrophils ( . These neutrophil responses were highly variable after LTA instillation, and as a consequence none of these neutrophil activation markers were altered by LTA in a statistically significant way. 
Gene expression profiles in alveolar macrophages
To reveal a possible differential responsiveness of alveolar macrophages to LPS and LTA in vivo, multiplex ligation-dependant probe amplification was performed on RNA isolated from purified alveolar macrophages harvested 6 hours after instillation of LTA or LPS (Table 2. 
Ex vivo cytokine release by alveolar macrophages
The gene expression profiles of alveolar macrophages purified from subjects challenged with either LPS or LTA, together with the (relative) inability of LTA to induce cytokine release in BALF in vivo, suggested that alveolar macrophages might be less activated by LTA. To obtain further proof for this we incubated purified alveolar macrophages harvested 6 hours after LPS or LTA instillation for 20 hours at 37 o C and measured spontaneous cytokine release in the supernatants. Due to the relatively low yield of alveolar macrophages after LTA instillation (most cells were used for RNA isolation), these incubations could only be done for 3 LTA challenged subjects (versus 8 LPS instilled subjects). When compared to alveolar macrophages harvested from the saline control lung, alveolar macrophages from the LPS challenged lung spontaneously released significant quantities of IL-1β, IL-6 and IL-8, but not of TNF-α (Figure 2 .5). In contrast, alveolar macrophages obtained from the LTA instilled lung released only small amounts of all 4 cytokines in all 3 subjects (Figure 2 .5). Remarkably, in LTA challenged subjects a variable response was seen with regard to alveolar macrophages from the saline control lung, where 2 of 3 subjects showed enhanced release of cytokines. Of note, however, due to the low number of observations no firm conclusions can be drawn with regard to the activation state of alveolar macrophages harvested from the saline control lung in LTA challenged subjects. 
Ex vivo dose response to LTA and LPS of human alveolar macrophages
Following the observation that alveolar macrophages might be less or not responsive to in vivo LTA stimulation, we stimulated normal human alveolar macrophages ex vivo with either 0.1, 1.0 and 10 μg/ml LPS or with 0.1, 1.0 and 10 μg/ml LTA. In concordance with the in vivo findings, alveolar macrophages did not produce or hardly produced any cytokines upon ex vivo stimulation, whereas a significant dose 
Discussion
Bacterial pneumonia is one of the most common infectious diseases and the leading cause of sepsis. In light of the prominent attribution of gram-positive pathogens pneumonia, we were interested to investigate the effect of LTA, an important proinflammatory component of gram-positive bacteria, in the human lung. This study reports for the first time a detailed analysis of the in vivo effects of LTA on lung inflammation in human volunteers. Our results demonstrate that LTA instillation into a pulmonary segment results in localized inflammation, manifested by neutrophil influx and elevated levels of neutrophil attractants, in the absence of detectable activation of alveolar macrophages. Previously, enhanced inflammatory responses in the lung have been observed in response to local administration of LPS in vivo 9, 11 . We here demonstrate that the inflammatory profile upon LTA instillation clearly differs from local LPS challenge.
The LTA used in this study was purified based on a relatively novel technique making use of a gentle extraction procedure using butanol 27 . Many studies involving LTA, especially those using commercially available preparations, are confounded by contaminating products 33 and by the fact that purification methods using a phenol extraction step result in decomposition of LTA especially in the loss of its alanine substituents 27 . The bioactive LTA preparation used here activated monocytes to release cytokines and is free of impurities such as LPS 27 . In the LTA dose escalation study we sought to find a dose at which LTA elicited a comparable influx of neutrophils into the bronchoalveolar compartment as LPS given at a dose (4 ng/kg) used in previous studies in human subjects 9, 10 . This dose response study established that 100 ng/kg LTA was required to provoke neutrophil influx to a similar extent as LPS. This difference in relative potency between LTA and LPS was expected in light of earlier studies examining the pulmonary effects of these bacterial constituents in mice 12, 14, 34, 35 . Of note, in this research model we also demonstrated that instillation of either LTA or LPS in the human lung resulted in activation of coagulation and inhibition of fibrinolysis 36 .
In line with previous studies, the number of macrophages recovered from BALF was not influenced 6 hours after LPS challenge 9, 11 . Remarkably, instillation of LTA tended to decrease the number of macrophages compared to saline, an effect that already was apparent at the lowest LTA dose. Two studies in mice documented a modest decrease in the number of alveolar macrophages after intrapulmonary delivery of LTA 35, 37 , although this was not found in other murine studies 12, 14 . Although a clear explanation for this phenomenon is lacking, it is possible that LTA induces increased adhesiveness of alveolar macrophages to the respiratory epithelium thereby reducing their recovery during BAL. Our finding that LPS stimulation caused neutrophil activation as shown by the release of degranulation markers elastase, MPO and BPI, confirms previous studies 9, 11 . LTA, however, only showed a tendency towards elevation. It remains to be established whether highly purified LTA can directly activate neutrophils. Whereas some investigations reported activation of purified human neutrophils upon exposure to LTA in vitro 38, 39 , another study was not able to detect such an effect 12 . Of note, neutrophils do express the receptors required for LTA signaling, i.e. CD14, TLR2 and TLR6 12, 38, 39 .
Surprisingly, unlike LPS, LTA elicited modest inflammatory responses in the contralateral saline-challenged lung, which was especially true for neutrophil influx and C5a release. Previously, others have demonstrated that focal lung injury often results in neutrophil emigration at distant sites. Focal instillation of S. pneumoniae induced neutrophil emigration in the contralateral region in rabbits 40 . Motosugi et al.
showed that focal hydrochloric (HCl) aspiration induced adhesion-complex CD11b/CD18-independent neutrophil emigration on the side of the lung damage and CD11b-dependant neutrophil emigration in the contralateral lung in rats 41 . In the current study, neutrophils obtained from both the saline-and LTA-challenged lung segments in LTA-volunteers showed equal CD11b neutrophil surface expression. However, in LPS-volunteers CD11b neutrophil surface expression was profoundly upregulated in the LPS-challenged lung compared to their saline-challenged lung segment. This finding suggests that LTA-and LPS-induced neutrophil adhesion and migration are differentially mediated in the human lung, which is in line with animal experiments showing that gram-negative bacteria elicit neutrophil emigration requiring CD11b/CD18-adhesion complex, while neutrophil emigration induced by gram-positive bacteria does not require the CD11b/CD18 adhesion pathway in the lung 42 .
Since instillation of LTA caused only moderate if any elevations in the BALF levels of neutrophil active chemokines, it is conceivable that the strongly increased C5a concentrations contributed importantly to the LTA-induced neutrophil recruitment. Interestingly, C5a levels were not influenced by LPS instillation. Since C5aR is mainly expressed by bronchial and alveolar epithelial cells in the human lung 43 , it is tempting to speculate that activation of epithelial cells plays an important role in LTA-induced inflammation. In this respect it is interesting to note that LTA can activate respiratory epithelial cells via the platelet activating factor receptor 44 . This notion is further corroborated by the absence of significant proinflammatory gene expression in alveolar macrophages obtained from LTA challenged lung segments, as well as by the absence of spontaneous cytokine release by these same cells upon ex vivo culture. IP-10 production upon LPS instillation is in line with the fact that IP-10 is produced TRIF/IRF3-dependently and is consequently not increased after TLR2 activation by LTA 45 .
To obtain insight into the specific role of alveolar macrophages in LTA-induced lung inflammation, we determined expression of mRNAs encoding a series of inflammatory mediators in isolated alveolar macrophages. Remarkably, mRNA expression of proinflammatory mediators IL-6, IL-1α, IL-1β, IL-8, MCP-1, MIP-1α, MIP-1β and signaling factors IκBα and NFκB1 were not upregulated in alveolar macrophages from LTAvolunteers, whereas the mRNAs encoding these mediators were significantly upregulated in LPS-volunteers. The latter is in line with a previous study wherein healthy subjects inhaled aerolized LPS 11 . Clearly, alveolar macrophages play a different role in LTA versus LPS signaling. In accordance with our previous human study 11 , LPS instillation resulted in detectable TNF-α protein levels in BALF in the absence of detectable TNF-α mRNA levels in alveolar macrophages. Conceivably, TNF-α mRNA was expressed by alveolar macrophages at time points earlier than 6 hours and/or by other cell types.
The current study has several limitations. First, the model of bronchial instillation involves the administration of relatively low doses of LTA and LPS into a single lung segment, which differs significantly from the clinical setting of acute lung injury or pneumonia. Furthermore, the (relative) unresponsiveness of alveolar macrophages to LTA might be a matter of the dose of LTA used in this study. However, this is contradicted by the significantly enhanced neutrophil influx upon LTA instillation (Figure 2 .1B) and the inability of human alveolar macrophages to produce cytokines upon incubation with high doses of LTA ex vivo (Figure 2.6 ). Secondly, a kinetic analysis over multiple time-points of especially LTA effects would be of considerable 34 ⏐ Chapter 2 interest, but we chose not to expand the number of time-points in light of the invasive procedure to obtain BALF samples. This is also the reason why a relatively limited number of volunteers was studied. Although in particular the LTA challenge studies would have benefited from a larger number of volunteers, an estimated 30-150 subjects would have been required to have at least 80% power to obtain statistical differences compared to saline effects with regard to distinct inflammatory responses such as neutrophil degranulation and cytokine/chemokine release (based on the interindividual variability in these inflammatory responses). Moreover, one should realize that the inflammatory response 6 hours post-challenge is likely to be a combination of the inflammatory response generated by the initial stimulus and then amplified by secondary endogenous inflammatory mediators generated during the inflammatory response. At present it is unclear whether gram-positive and gramnegative bacteria induce distinct pulmonary inflammatory responses in humans in vivo. Of note, however, intact bacteria express multiple PAMPs that can interact with different TLRs, making a direct comparison with responses to purified TLR2 and TLR4 agonists difficult.
In conclusion, the present study is the first to provide insight into the in vivo effects of LTA in the human lung. Further studies are needed to evaluate the specific contribution of macrophages and respiratory epithelium in LTA-induced inflammation. This novel human model may be used to evaluate pathogenic mechanisms at play during gram-positive respiratory tract infection.
